Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Synergistic Intervention of Minimally Invasive Surgery and Deferoxamine in Intracerebral Hemorrhage (SMAD)

NCT07162363 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT07162363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07162363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Synergistic Intervention of Minimally Invasive Surgery and Deferoxamine in Intracerebral Hemorrhage (SMAD)
Lead sponsor
University of Illinois at Chicago
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
December 30, 2028
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ich - intracerebral hemorrhage, intracerebral hemorrhage